Chinese consensus on management of tyrosine kinase inhibitor-associated side effects in gastrointestinal stromal tumors-Reference-Cited by-同舟云学术

Chinese consensus on management of tyrosine kinase inhibitor-associated side effects in gastrointestinal stromal tumors

Published:2018-12-14 Issue:46 Volume:24 Page:5189-5202
ISSN:1007-9327
Container-title:World Journal of Gastroenterology
language:
Short-container-title:WJG

Author:

Li Jian,Wang Ming,Zhang Bo,Wu Xin,Lin Tian-Long,Liu Xiu-Feng,Zhou Ye,Zhang Xin-Hua,Xu Hao,Shen Li-Jing,Zou Jing,Lu Ping,Zhang Dong,Gu Wei-Jun,Zhang Mei-Xia,Pan Jian,Cao Hui

Publisher

Baishideng Publishing Group Inc.

Subject

Gastroenterology,General Medicine

Reference111 articles.

1. GRADE guidelines: 3. Rating the quality of evidence

2. Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal Tumors

3. Sutent® Summary of Product Characteristics 2008. Sandwich, Kent, UK: Pfizer Ltd

4. Practical Management of Patients With Chronic Myeloid Leukemia Receiving Imatinib

5. Practical management of tyrosine kinase inhibitor-associated side effects in GIST

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Untargeted metabolomics analysis reveals the potential mechanism of imatinib-induced skin rash in patients with gastrointestinal stromal tumor;International Immunopharmacology;2024-10

2. Gene polymorphisms affect postoperative imatinib plasma levels and edema in adults with gastrointestinal stromal tumor;Pharmacogenomics;2023-05

3. Pembrolizumab plus lenvatinib for radically unresectable or metastatic renal cell carcinoma in the Japanese population;Expert Review of Anticancer Therapy;2023-04-10

4. Perioperative Care: Sarcoma and Melanoma;Perioperative Care of the Cancer Patient;2023

5. Genetic polymorphisms are associated with imatinib plasma levels and periorbital edema in Chinese patients with gastrointestinal stromal tumors receiving adjuvant imatinib;2022-08-26